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Summary Mediastinal masses include a wide variety of tumours and remain an interesting diagnostic
challenge for radiologists. We performed positron emission tomography (PET) studies of primary mediastinal
tumours in order to predict the malignancy of these tumours preoperatively. Twenty-two patients with primary
mediastinal tumours were studied with PET using 2-deoxy-2-[18F]fluoro-D-glucose (FDG). The histological
findings of surgical pathology or biopsy, or mediastinoscopy were compared with those of computerised
tomography (CT) and PET. PET images were evaluated semiquantitatively using the differential uptake ratio
(DUR). Increased FDG uptake was observed in nine of ten patients with malignant tumours, including thymic
carcinomas, lymphomas, invasive thymomas and a case of sarcoidosis. A moderate level of FDG uptake was
found in a myeloma, non-invasive thymomas, and a schwannoma, whereas a low uptake was observed in a
teratoma and various benign cysts. The mean FDG uptake of malignant tumours was significantly higher than
that of benign tumours. Both thymic cancer and invasive thymoma showed a high FDG uptake, whereas non-
invasive thymoma and other benign tumours showed a low FDG uptake. CT examination resulted in three
false-negative and two false-positive cases when used in predicting tumour invasion, while PET was associated
with a false-positive and a false-negative case. In conclusion, the use of FDG with PET is clinically helpful in
evaluating the malignant nature of primary mediastinal tumours. Our results also suggest that a high FDG
uptake reflects the invasiveness or malignant nature of thymic tumours.
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Mediastinal masses include a wide variety of tumours, and
remain an interesting diagnostic challenge for radiologists.
Computerised tomography (CT) has proved to be an
excellent diagnostic tool for investigating the mediastinum
(Cohen et al., 1991; Davis et al., 1987; Graeber et al., 1986).
CT can delineate the location and extent of mediastinal
tumours, as well as the involvement of adjacent tissue.
Whereas obliteration of the peritumoral fat planes corre-
sponds with invasion and is a sign of malignancy, fibrous
adhesion of the tumour without invasion may be confused
with infiltration of the tumour. When the fat planes are
partially preserved, only about half of the tumours are
invasive (Chen et al., 1988; Rendina et al., 1988). The CT
demonstration of fat, calcium or water attenuation in a
tumour often suggests a specific diagnosis. However, the
ability of CT to differentiate soft tissue mediastinal masses is
limited, owing to a considerable overlap in the CT
characteristics between malignant and benign tumours
(Rendina et al., 1988; Rebner et al., 1987).
Magnetic resonance imaging (MRI) is also useful in
evaluating mediastinal tumours (Aronberg et al., 1985;
Brown et al., 1991). The advantages of MRI are direct
multiplane imaging of tumour invasion. MRI has a better
contrast resolution and is more reliable than CT in detecting
cystic tumours, fat in a tumour and vascular diseases.
However, an overlap in Ti and T2 parameters of MRI has
been demonstrated between benign and malignant tumours
(Link et al., 1993).
Positron emission tomography (PET) has proved excellent
in detecting malignant tumours of the central nervous system
(CNS) and non-CNS tumours (Strauss and Conti, 1991).
Both 2-deoxy-2-fluoro-[18F]-D-glucose (FDG) and L-
[Methyl-11C]methionine (Met) have been used with PET for
the diagnosis of head and neck (Minn et al., 1988; Leskinen-
Kallio et al., 1992), breast (Leskinen-Kallio et al., 1991; Wahl
et al., 1991), and lung (Kubota et al., 1990, Patz et al., 1993)
cancers. FDG has also been used in detecting liver tumours
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(Okazumi et al., 1992) and pancreas cancer (Bares et al.,
1994). To our knowledge, the use of FDG in primary
mediastinal tumours has not yet been evaluated. In order to
predict the malignant nature of these tumours preoperatively,
we performed PET studies using FDG and compared the
results with the pathological diagnosis and the results of CT
examination.
Materials and methods
Patients
A total of 22 patients (mean age 50+19(±s.d.), range 14-
83, 12 women and ten men) with mediastinal tumours were
studied with PET imaging. Sixteen patients had anterior, four
patients had middle, and two patients had posterior
mediastinal tumours. Tumour size was from 8 cm to 3.5 cm
maximum diameter with CT. None received chemo- or
radiotherapy before the PET study. Patients with primary
malignant tumours of the lung, oesophagus or other organs
were excluded from this study. There were no diabetic
patients and the mean body mass index [body weight (kg) /
height (m)2] was 23.7+3.5 (range 17.8-29.6) (Table I).
The study protocol was approved by the Ethics Committee
for Clinical Research of Tohoku University and informed
consent was obtained from each patient.
PET imaging and analysis
Twenty-two patients were studied using FDG. FDG was
prepared using an automated synthesis system, and quality
assurance tests were performed as described previously
(Kubota et al., 1990). After fasting for 5 h the blood glucose
level was measured before the injection of FDG. PET scans
were performed using a PT931/04 scanner (Siemen-CTI,
Knoxville, TN, USA) employing seven 7.15-mm wide slices,
simultaneous acquisition, with 50 mm axial field of view
(resolution: 7.1 mm of full-width half-maximum (FWHM).
No tumour was smaller than 2.5 cmx3.0 cm in diameter,
and we considered that the calibration of the count recovery
might not be essential because it is said that an object of thePET for mediastinal tumours
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Table I Patients' data of FDG-PET study
Patient CT Tumour Glucose
number Age/sex Location Histology Cell type invasion DUR (mg dl') BMI
1 68M Ant. Invasive thymoma Mixed + 10.04 91 21.9
2 62F Ant. Invasive thymoma Lym. pred. - (FN) 9.86 116 21.6
3 74M Ant. Thymic cancer Small cell + 8.58 103 19.8
4 21F Ant. Hodgkin's disease - (FN) 7.92 90 23.2
5 83F Ant. Thymic cancer + 7.74 113 22.6
6 68M Ant. Thymic cancer Small cell + 7.22 96 20.1
7 73F Ant. chest Non-Hodgkin's lymphoma + 6.90 - 17.8
8 35M Ant. Invasive thymoma Epith. pred. (FN) 5.96 94 20.8
9 34M Middle Sarcoidosis _ (FP)4.99 110 27.4
10 53M Middle Squamous cell carcinoma + 4.57 107 28.2
11 56F Ant. ster. IgG myloma + (FN)2.72 101 22.8
12 58M Ant. Non-invasive thymoma Mixed + (FP) 2.63 88 26.0
13 58F Ant. Non-invasive thymoma Lym. pred. - 2.58 97 27.9
14 70M Ant. Non-invasive thymoma Spindle cell - 2.24 99 26.4
15 25M Post. Schwannoma - 1.99 90 23.9
16 5OF Ant. Non-invasive thymoma Lym. pred. - 1.76 128 25.5
17 41F Middle Bronchogenic cyst - 1.30 89 23.6
18 39F Middle Bronchogenic cyst - 1.10 91 26.6
19 5OF Ant. Pericardial cyst - 0.91 99 27.6
20 14M Ant. Teratoma - 0.90 86 19.6
21 24F Ant. Dermoid cyst - 0.64 72 18.2
22 53F Post. Bronchogenic cyst + (FP) 0.61 112 29.6
M, male; F, female; Ant., anterior mediastinum; Ant. chest, anterior mediastinum and chest wall; Ant. ster., anterior mediastinum and sternum;
Post., posteriormediastinum; Lym. pred., lymphocyte predominant; Epith. pred., epithelial cell predominant; FN, false negative; FP, false positive;
Glucose, blood glucose level; BMI, body mass index = body weight (kg)/[height (m)2].
size three times larger than FWHM shows more than 80% of
count recovery (Mazziota et al., 1981). After a transmission
scan using germanium-68/gallium-68 ring source for the
attenuation correction, a bolus dose of FDG was injected
intravenously. The mean dose of FDG was 4.8+0.8 mCi
(177.6 +29.6 MBq). Dynamic images were obtained first,
followed by a 10 min static image that was acquired 45-55
min after injection of FDG. The PET images were
reconstructed using a measured attenuation, dead time and
decay correction factors. There was no significant patient
movement or mis-positioning between transmission scan and
emission scan. This was checked with the markers attached to
the patient and the laser pointers of the scanner during the
examination. Evaluation of data was performed before tissue
biopsy or surgery and histological diagnosis. Static images on
film were examined and compared with CT scans by four
observers (KK, HF, TF, MI). In order to have the
anatomical orientation of the PET image, CT images were
used. Then, the tumour uptake was assessed by an observer
(KK), using the region of interest (ROI) technique. The
tumour ROI was set on the static image. In large tumours
ROI was placed at the periphery of tumour including the
highest radioactivity point, so that it included minimum
necrotic tissue. The actual size of the tumour ROI varied
from 2 to 6 cm2 depending on the tumour size. To avoid
contamination of the non-tumour area, the tumour ROls
were checked carefully by superimposing both on transmis-
sion images and on the early post injection images, which
showed vascular structures.
The mean radioactivity per pixel within the tumour ROI
was quantitatively analysed by calculating the differential
uptake ratio (DUR; synonym standardised uptake value,
SUV), as reported previously (Kubota et al., 1985).
DUR Radioactivity concentration in ROI (Bq mm-3)
Injected dose (Bq)/weight of patient (g)
Mean DURs in tumour groups were compared with mean
DURs in the benign lesions using Student's t test.
CT and pathological diagnosis
All patients had CT imaging within 2 weeks before the PET
study. The image level of the PET study was determined by
CT and chest radiological examination. Because only a few
patients had MRI in this study, the results of MRI were not
reported in the present study. CT images were evaluated
before PET study. Diagnostic criterion of invasiveness with
CT is based on the obliteration of the peritumoral fat planes
or signs of direct invasion to adjacent structures. Histological
diagnosis was determined in all patients after the PET study
by surgical pathology (14 patients) or biopsy (eight patients),
and the histological diagnosis was compared with results of
the PET study. Thymic tumours were classified as cytological
benign (thymoma) or malignant (thymic cancer) depending
on the conventional cytological criteria. Thymoma was
classified as invasive or non-invasive. It is based on the
microscopic demonstration of tumour cell invasion to the
outside of the capsule of the tumours resected by surgery,
biopsy or macroscopic demonstration of gross invasion of
tumour tissue to adjacent structure by mediastinoscopy.
Invasive thymoma is considered as clinically malignant, and
non-invasive thymoma as clinically benign.
Results
The clinical characteristics of patients and results of FDG
studies are shown in Table I. A high FDG uptake (DUR >4)
was clearly observed in nine of ten patients with clinically
malignant tumours, and also in one patient with sarcoidosis.
A moderate level of FDG (DUR> 1.5) uptake was observed
in non-invasive thymomas, a myeloma and schwannoma,
whereas a low FDG uptake (1.5 > DUR) was detected in a
teratoma and various benign cysts. The cut-off line of
malignant tumour seems to be about 3.5 by DUR. The
mean FDG uptake was significantly higher in clinically
malignant tumours compared with that of benign tumour
using DUR (Table II). The blood glucose levels in malignant
tumours were not significantly different from those in benign
tumours. The mean body mass index of benign tumours was
slightly higher than that of malignant tumours. Example of
typical PET images of invasive thymoma (Figure 1) and non-
invasive thymoma (Figure 2) are presented.
Variable results were obtained with CT. In general, a
specific diagnosis using CT was difficult when the tumour
showed a soft tissue density. We, therefore, examined the CT
in the diagnosis of tumour invasion (Table I). False-negative
results were noted in two cases of invasive thymomas and a
case of Hodgkin's disease, and false-positive in a non-invasivePET for mediastinal tumours
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thymoma with fibrous adhesions demonstrated during
surgery. Another false positive CT was noted in a
bronchogenic cyst. CT correctly diagnosed the tumour
invasion in 17 patients (sensitivity 70%, specificity 83%,
accuracy 77%). FDG-PET showed a false positive of
sarcoidosis, and a false negative of a myeloma and correctly
predicted the nature of the tumour in 20 patients (sensitivity
90%, specificity 92%, accuracy 91%). Thus, in this limited
series of patients, PET seems to be superior to CT in
predicting the nature of mediastinal tumours.
The distribution of DUR in malignant and benign
tumours with FDG is shown (Figure 3). The use of FDG
enabled differentiation of most malignant tumours from
benign tumours based on DUR analysis. However, there was
an overlap between malignant and benign tumours.
Table III summarises the FDG uptake by thymic tumours.
Invasive thymomas showed significantly higher FDG uptake
than non-invasive thymomas (P< 0.005) and other benign
tumours (P<0.001). Thymic cancer showed the same high
FDG uptake as invasive thymoma.
Table II FDG uptake by benign and malignant mediastinal
tumours
Tumour Glucose
DUR (mg dl1) BMI
Malignant (l0)a 7.15 ±2.27b 101±9c 21.9 ±2.8d
Benign (12) 1.80± 1.24 97± 15 25.2±3.4
Means+ s.d. aNumber of patients. bp<0.001 compared with
benign tumours. CNot significant compared with benign tumours
(Student's t test). d P <0.05 compared with benign tumour. Glucose,
blood glucose level; BMI, body mass index.
Figure 1 A typical FDG-PET image (a) and CT (b) of an
invasive thymoma, patient no.l. 45-55 min after injection of 5
mCi (185 MBq) of FDG, showing an increased FDG uptake by
tumour (DUR: 10.04).
Figure 2 A typical FDG-PET image (a) and CT (b) of a non-
invasive thymoma, patient no.12, 45-55 min after injection of 4.5
mCi (167 MBq) of FDG, showing a low FDG uptake by tumour
(DUR: 2.63).
Discussion
The major finding of the present study is that the distribution
of FDG uptake in malignant mediastinal tumours, revealed
by PET, was significantly higher than that in benign tumours.
These results are in agreement with those reported recently
on the excellent diagnostic performance of PET in
differentiating the malignancy of lung nodules using FDG-
PET. These studies demonstrated that the sensitivity of FDG-
PET in detecting lung cancers of more than 1 cm in diameter
as malignant tumours was 95-98% with a specificity of 83-
94% (Kubota et al., 1990; Patz et al., 1993; Dewan et al.,
1993). The present results are also consistent with FDG-PET
studies of other tumours, including breast (Adler et al., 1993)
and pancreatic tumours (Bares et al., 1994). These results
suggest that the high uptake of FDG seems to be a general
feature of a variety of cancers. Increased FDG uptake may
reflect the high activity of hexokinase and glucose transport
(Haberkorn et al., 1994).
Calculation of the glucose metabolic rate using FDG
based on Sokoloffs model has been applied to oncology
PET, mostly to brain tumour studies (Di Chiro, 1987).
However, this method requires arterial blood sampling and
estimation of the lumped constant. Determination of the
latter in individual tumours is impossible in humans. More
simple evaluation methods without blood sampling, such as
DUR or tumour-normal tissue ratio, have been recently
introduced. The clinical value of these parameters has been
demonstrated in several oncology studies. Zasadny and Wahl
(1993) recently proposed the calibration of the FDG uptake
with respect to body surface area or lean body weight,
particularly in obese patients, instead of body weight. The10
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Figure 3 The distribution of DUR of FDG in malignant (A)
and benign (0) primary mediastinal tumours. Mean FDG uptake
of malignant tumour is 7.15+2.27, benign tumour is 1.80+1.24.
Table III FDG uptake by thymic tumours
Histology (n) DUR
Thymic cancer (3) 7.85 +0.69
Invasive thymoma (3) 8.62+2.31*
Non-invasive thymoma (4) 2.30 +0.40
Other benign tumours (8) 1.56±1.46
Means +s.d. *P <0.005 compared with non-invasive thymoma and
P < 0.001 compared with other benign tumours. Not significant
compared with thymic cancers (Student's t test).
FDG uptake of lung and head and neck tumours decreased
significantly in the presence of hyperglycaemia (Lindholm et
al., 1993; Langen et al., 1993). Our study did not include such
obese patients as they have reported (BW 80-107 kg) and,
furthermore, the blood glucose level was the same in patients
with malignant and benign tumours. Therefore, technical
errors in our PET measurements are unlikely.
A false-positive high FDG uptake was observed in
sarcoidosis in the present study. Similar studies have recently
described increased FDG uptake by enlarged lymph nodes
(Lewis and Salama, 1994) and lung tissue (Brudin et al.,
1994) in sarcoidosis. Since sarcoid nodules consist of
PET for mediastinal tumours
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epidermoid cells that have, together with the macrophages,
a common precursor cell, the monocyte, we believe that the
high FDG uptake by the sarcoid tissue is a similar
phenomenon to that by macrophages. This is supported by
experimental demonstration of increased FDG uptake by
macrophages (Kubota et al., 1992).
The level of FDG uptake of tumours is related to the
grade of malignancy in brain and soft tissue tumours (Di
Chiro, 1987; Adler et al., 1991). Furthermore, it has also been
used as a prognostic indicator of malignancy in gliomas
(Patronas et al., 1985). The FDG uptake by the tumour also
correlates with the cell density in grade 2 and 3 gliomas
(Herholz et al., 1993). Results ofexperimental studies indicate
that the uptake of FDG is related to the number of viable
cancer cells in vitro (Higashi et al., 1993), and the amount of
viable tissue in vivo (Kubota et al., 1993). FDG uptake varies
also with the histological differentiation of human abdominal
tumours transplanted in nude mice (Yoshioka et al., 1994). In
this regard, recent studies from our laboratory indicate that
FDG uptake by cancer cells is higher in GO/GI and G2 phases
of the cell cycle compared with the S- and M-phases (Kubota
et al., 1994), and that tumour growth rates correlated with
the FDG uptake of tumours (Kubota et al., 1995). These
results suggest that uptake of FDG by mediastinal tumours
may represent a biological marker of the clinical behaviour of
these tumours.
Thymomas are classified cytologically into benign or
malignant. However, a proportion of the cytologically
benign thymomas is locally invasive and has clinical features
of malignancy. Thus, cytological classification may not be
always prognostically useful (Lewis et al., 1987). Our PET
study demonstrated a high FDG uptake by thymic cancers
and invasive thymomas. These results add support to the
clinical practice that both thymic cancers and invasive
thymomas should be treated as malignant tumours, while
only non-invasive thymomas should be considered benign
tumours (Lewis et al., 1987). The classification of thymomas
by PET in the present study agreed with the clinical rather
than the cytological classification. However, owing to the
small number of patients, a further confirmation of this
observation is necessary.
Single-photon emission computerised tomography
(SPECT) using 67Ga or 20'T1 has been used widely for
tumour imaging. Usefulness of 67Ga-SPECT for malignant
lymphoma in mediastinum has been well established (Front
et al., 1991). However, the uptake of 67Ga is non-specific for
malignant tumour (Tsan and Scheffel, 1986; Chandramouly
et al., 1989). The value of 67Ga for the differential diagnosis
of mediastinal tumour seems not to be high. 201TI-SPECT has
been used recently for the diagnosis of lung and other
tumours (Abdel-Dayem et al., 1994). Detection of thymoma
in patients ofmyasthenia gravis has been reported with 201Tl-
SPECT. However, they cannot differentiate malignant
tumour from benign thymoma (Tonami et al., 1993).
In conclusion, PET, using FDG, seems to be useful in the
evaluation of malignancy in primary mediastinal tumours.
Both thymic cancer and invasive thymoma showed high FDG
uptake, while non-invasive thymomas and other benign
tumours showed low uptake. A high FDG uptake seems to
reflect the invasiveness or malignant nature of thymic
tumours.
Acknowledgements
The authors thank Mr Sugawara for photography, Mr Watanuki
and Mr Seo for PET operation and Professor H Orihara, and the
staff of the Cyclotron and Radioisotope Center, Tohoku Uni-
versity, for their assistance. We also thank Dr FG Issa (Word-
Medex) for his assistance in reading and editing the manuscript.
This work was supported by grants-in-aid (06454320, 06670899,
07274206) from the Ministry of Education, Science and Culture,
Japan.
1' r- _ 12.5PET for mediastinal tumours
a* K Kubota et at
886
References
ABDEL-DAYEM HM, SCOTT AM, MACAPINLAC HA, EL-GAZZAR
AH AND LARSON SM. (1994). Role of 201TI chloride and 99mTc
sestamibi in tumor imaging. In Nuclear Medicine Annual 1994
Freeman LM (ed). Raven Press: New York, pp. 181-234.
ADLER LP, BLAIR HF, MAKLEY JT, WILLIAMS RP, JOYCE MJ,
LEISURE G, AL-KAIST N AND MIRALDI F. (1991). Noninvasive
grading ofmusculoskeletal tumors using PET. J. Nucl. Med., 32,
1508-1512.
ADLER LP, CROWE JP, AL-KAISI NK AND SUNSHINE JL. (1993).
Evaluation of breast masses and axillary lymph nodes with [F-
18]2-deoxy-2-fluoro-D-glucose PET. Radiology, 187, 743-750.
ARONBERG DJ, GLAZER HS AND SAGEL SS. (1985). MRI and CT of
the mediastinum comparisons, controversies, and pitfalls. Radiol.
Clin. North. Am., 23, 439-448.
BARES R, KLEVER P, HAUTMANN S, HELLWIG D, FASS J,
CREMERIUS U, SCHUMPELICK V, MITTERMAYER C AND
BULL U. (1994). F-18 fluorodeoxyglucose PET in vivo evaluation
of pancreatic glucose metabolism for detection of pancreatic
cancer. Radiology, 192, 79-86.
BROWN LR AND AUGHENBAUGH GL. (1991). Masses of the
anterior mediastinum: CT and MR imaging. Am. J. Roentgen-
ol., 157, 1171-1180.
BRUDIN LH, VALIND S-O, RHODES CG, PANTIN CF, SWEATMAN
M, JONES T AND HUGHES JMB. (1994). Fluorine-18 deoxyglucose
uptake in sarcoidosis measured with positron emission tomo-
graphy. Eur. J. Nucl. Med., 21, 297-305.
CHANDRAMOULY BS, SCAGNELLI T AND BURGESS C. (1989).
Uptake of gallium in the mediastinum. Semin. Nucl. Med., 19,
247-249.
CHEN J, WEISBROD GL AND HERMAN SJ. (1988). Computed
tomography and pathologic correlations of thymic lesions. J.
Thorac. Imaging, 3, 61-65.
COHEN AJ, THOMPSON L, EDWARDS FH AND BELLAMY RF.
(1991). Primary cysts and tumors of the mediastinum. Ann.
Thorac. Surg., 51, 378-386.
DAVIS JR RD, OLDHAM JR HN AND SABISTON JR DC. (1987).
Primary cysts and neoplasms ofthe mediastinum: recent changes
in clinical presentation, methods of diagnosis, management, and
results. Ann. Thorac. Surg., 44, 229-237.
DEWAN NA, GUPTA NC, REDEPENNING LS, PHALEN JJ AND
FRICK MP. (1993). Diagnostic efficacy of FDG-PET imaging in
solitary pulmonary nodules. Chest, 104, 997- 1002.
DI CHIRO G. (1987). Positron emission tomography using
[18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic
and prognostic tool. Invest. Radiol., 22, 360-371.
FRONT D, ISRAEL 0 AND BEN-HAIM S. (1991). The dilemma of a
residual mass in treated lymphoma: The role of callium-67
scintigraphy. In Nuclear Medicine Annual 1991, Freeman LM
(ed) Raven Press: New York. pp. 211-220.
GRAEBER GM, SHRIVER CD, ALBUS RA, BURTON NA, COLLINS
GJ, LOUGH FC AND ZAJTCHUK R. (1986). The use ofcomputed
tomography in the evaluation of mediastinal masses. J. Thorac.
Cardiovasc. Surg., 91, 662-666.
HABERKORN U, ZIEGLER SI, OBERDORFER F, TROJAN H, HAAG
D, PESCHKE P, BERGER MR, ALTMANN A AND VAN KAICK G.
(1994). FDG uptake, tumor proliferation and expression of
glycolysis associated genes in animal tumor models. Nucl. Med.
Biol., 21, 827-834.
HERHOLZ K, PIETRZYK U, VAGES J, SCHRODER R, HALBER M,
TREUER H, STURM V AND HEISS W-D. (1993). Correlation of
glucose consumption and tumor cell density in astrocytomas. J.
Neurosurg., 79, 853-858.
HIGASHI K, CLAVO AC AND WAHL RL. (1993). Does FDG uptake
measure proliferative activity of human cancer cells? In vivo
comparison with DNA flow cytometry and tritiated thymidine
uptake. J. Nucl. Med., 34, 414-419.
KUBOTA K, MATSUZAWA T, ITO M, FUJIWARA T, ABE Y,
YOSHIOKA S, FUKUDA H, HATAZAWA J, IWATA R, WATANUKI
S AND ITO T. (1985). Lung tumor imaging by positron emission
tomography using C-iIL-methionine. J. Nucl. Med., 26, 37-42.
KUBOTA K, MATSUZAWA T, FUJIWARA T, ITO M, HATAZAWA J,
ISHIWATA K, IWATA R AND IDO T. (1990). Differential diagnosis
of lung tumor with positron emission tomography: a prospective
study. J. Nucl. Med., 31, 1927-1933.
KUBOTA R, YAMADA 5, KUBOTA K, ISHIWATA K, TAMAHASHI N
AND IDO T. (1992). Intratumoral distribution of fluorine-18-
fluorodeoxyglucose in vivo: high accumulation in macrophages
and granulation tissues studied by microautoradiography. J.
Nucl. Med., 33, 1972-1980.
KUBOTA K, KUBOTA R AND YAMADA S. (1993). FDG accumula-
tion in tumor tissue. J. Nucl. Med., 34, 419-421.
KUBOTA R, KUBOTA K, YAMADA S, TADA M, IDO T AND
TAMAHASHI N. (1994). Active and passive mechanisms of
[fluorine-18]fluorodeoxyglucose uptake by proliferating and
prenecrotic cancer cells in vivo: a microautoradiographic study.
J. Nucl. Med., 35, 1067- 1075.
KUBOTA R, KUBOTA K, YAMADA S, TADA M, TAKAHASHI T,
IWATA R AND TAMAHASHI N. (1995). Methionine uptake by
tumor tissue: a microautoradiographic comparison with FDG. J.
Nucl. Med., 36, 484-492.
LANGEN KJ, BRAUN U, KOPS R, HERZOG H, KUWERT T,
NEBELING B AND FEINENDEGEN LE. (1993). The influence of
plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake
in bronchial carcinomas. J. Nucl. Med., 34, 355-359.
LESKINEN-KALLIO S, NAGREN K, LEHIKOINEN P, RUOTSALAI-
NEN R AND JOENSUU H. (1991). Uptake of "C-methionine in
breast cancer studied by PET. An association with the size of S-
phase fraction. Br. J. Cancer, 64, 1121 - 1124.
LESKINEN-KALLIO S, NAGREN K, LEHIKOINEN P, RUOTSALAI-
NEN U, TERAS M AND JOENSUU H. (1992). Carbon-11-
methionine and PET is an effective method to image head and
neck cancer. J. Nucl. Med., 33, 691-695.
LEWIS JE, WICK MR, SCHEITHAUER BW, BERNATZ PE AND
TAYLOR WF. (1987). Thymoma: a clinicopathologic review.
Cancer, 60, 2727-2743.
LEWIS PJ AND SALAMA A. (1994). Uptake of fluorine-18-
fluorodeoxyglucose in sarcoidosis. J. Nucl. Med., 35, 1647- 1649.
LINDHOLM P, MINN H, LESKINEN-KALLIO S, BERGMAN J,
RUOTSALAINEN U AND JOENSUU H. (1993). Influence of the
blood glucose concentration on FDG uptake in cancer - a PET
study. J. Nucl. Med., 34, 1-6.
LINK KM, SAMUELS LJ, REED JC, LOEHR SP AND LESKO NM.
(1993). Magnetic resonance imaging of the mediastinum. J.
Thorac. Imaging, 8, 34-53.
MAZZIOTA JC, PHELPS ME, PLUMMER D AND KUHL DE. (1981).
Quantitation in positron emission computed tomography: 5
Physical-anatomical effects. J. Comput. Assist. Tomogr., 5, 734-
743.
MINN H, JOENSUU H, AHONEN A AND KLEMI P. (1988).
Fluorodeoxyglucose imaging: a method to assess the prolifera-
tive activity of human cancer in vivo. Cancer, 61, 1776- 1781.
OKAZUMI S, ISONO K, ENOMOTO K, KIKUCHI T, OZAKI M,
YAMAMOTO H, HAYASHI H, ASANO T AND RYU M. (1992).
Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose
PET: characterisation of tumor and assessment of effect of
treatment. J. Nucl. Med., 33, 333-339.
PATRONAS NJ, DI CHIRO G, KUFTA C, BAIRAMIAN D, KORN-
BLITH PL, SIMON R AND LARSON SM. (1985). Prediction of
survival in glioma patients by means of positron emission
tomography. J. Neurosurg., 62, 816-822.
PATZ EF, LOWE VJ, HOFFMAN JM, PAINE S, BURROWES P,
COLEMAN RE AND GOODMAN PC. (1993). Focal pulmonary
abnormalities: evaluation with F-18 fluorodeoxyglucose PET
scanning. Radiology, 188, 487-490.
REBNER M, GROSS BH, ROBERTSON JM, PENNES DR, SPIZARNY
DL AND GLAZER GM. (1987). CT evaluation of mediastinal
masses. Comput. Radiol., 11, 103 - 110.
RENDINA EA, VENUTA F, CERONI L, MARTELLI M, GUALDI G,
CATERINO M AND RICCI C. (1988). Computed tomographic
staging of anterior mediastinal neoplasms. Thorax, 43, 441 -445.
STRAUSS LG AND CONTI PS. (1991). The application of PET in
clinical oncology. J. Nucl. Med., 32, 623 -648.
TONAMI N, YOKOYAMA M, TAKI J, SHUKE N, MIYAUCHI T,
MICHIGISHI T, ABURANO T AND HISADA K. (1993). Detection
of thymic abnormality in myasthenia gravis with thallium-201
SPECT. J. Nucl. Med., 34, 223p.
TSAN MF AND SCHEFFEL U. (1986). Mechanism of gallium-67
accumulation in tumours. J. Nucl. Med., 27, 1215- 1219.
WAHL RL, CODY RL, HUTCHINS GD AND MUDGETT EE. (1991).
Primary and metastatic breast carcinoma: Initial clinical
evaluation with PET with the radiolabelled glucose analogue 2-
[F-18]-fluoro-2-deoxy-D-glucose. Radiology, 179, 765-770.
YOSHIOKA T, TAKAHASHI H, OIKAWA H, MAEDA S, WAKUI A,
WATANABE T, TEZUKA F, TAKAHASHI T, IDO T AND
KANAMARU R. (1994). Accumulation of 2-deoxy-2-['8F]fluoro-
D-glucose in human cancer heterotransplanted in nude mice:
comparison between histology and glycolytic status. J. Nuci.
Med., 35, 97-103.
ZASADNY KR AND WAHL RL. (1993). Standardised uptake values of
normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-
glucose: variations with body weight and a method for
correction. Radiology, 189, 847-850.